BioDlink International Company Limited
Research BioDlink International Company Limited (1875.HK) on Bullrun: market cap HKD 2.55B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1875.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 2.55B
- Financial periodFY2025
- RevenueCNY 747.65M
- Revenue growth-31.9%
- Net income-CNY 100.37M
- Free cash flow-CNY 26.93M
- Gross margin52.0%
Valuation Snapshot
latest market cap is HKD 2.55B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 747.65M | -CNY 100.37M | -CNY 26.93M | 52.0% | n/a | CNY 327.56M | CNY 383.56M | CNY 625.82M |
| FY2024 | CNY 1.10B | CNY 34.76M | -CNY 7.17M | 71.2% | 0.05 | CNY 381.26M | CNY 395.47M | CNY 729.66M |
| FY2023 | CNY 780.63M | -CNY 37.76M | -CNY 146.77M | 73.5% | -0.05 | CNY 351.60M | CNY 345.65M | CNY 686.69M |
| FY2022 | CNY 442.18M | -CNY 49.92M | -CNY 180.19M | 83.8% | -0.08 | CNY 417.77M | CNY 289.53M | CNY 713.88M |
| FY2021 | n/a | n/a | n/a | n/a | -0.46 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.55B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About BioDlink International Company Limited
BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioDlink International Company Limited's market cap?
BioDlink International Company Limited's market capitalization is HKD 2.55B.
What does BioDlink International Company Limited do?
BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma.